Bayer's painkiller Aleve carries the same heart-risk warning as other nonsteroidal anti-inflammatories, or NSAIDs, like Motrin and Advil. And as far as an FDA review panel of experts is concerned, it should continue to.
AstraZeneca's diabetes drug Onglyza is under the FDA's microscope. The agency said it would review possible heart risks associated with the medication, which is one of the cornerstone products in the U.K.-based drugmaker's diabetes business.
The number of new drug shortages in the U.S. has fallen dramatically during the last few years. Still, the total number of shortages keeps growing, leaving doctors to figure out how to change treatment plans when meds are unavailable.
The U.K.'s National Health Service hired a lobbying group, Specialised Healthcare Alliance (SHCA), to write a report on strategies for care, which could influence health policy, The Guardian reports.
Are the BRIC countries passé in Big Pharma? Not exactly. But multinational pharma's newest trend lies in the Persian Gulf, the Wall Street Journal reports.
When Merck & Co. suddenly took over Merck KGaA's Facebook page, that was one thing. But when demonstrators showed up at the German Merck's London office--to protest a move by the U.S.-based Merck--that was something else entirely.
Mallinckrodt has taken a major step toward hitting its goal of boosting revenues as much as 11% a year by announcing it would acquire Cadence Pharmaceuticals for $1.3 billion, or $14 a share, a 26% premium over Cadence's closing price yesterday.
Federal prosecutors are eyeing Teva Pharmaceutical Industries for potential marketing violations.
Late last year, FDA Commissioner Margaret Hamburg's first official trip to India was postponed for undisclosed reasons. It was rescheduled and now happens to coincide with actions designed to put ultimate pressure on India over its low regard for patents on drugs that it thinks are too expensive.
If Big Pharma should consider hiving off extraneous business units, then why not Big Generics? Goldman Sachs analyst Jami Rubin, an early champion of the pharma breakup, figures Teva Pharmaceutical Industries could try it.
The President's Cancer Panel is urging federal and state health authorities to do a better job protecting children from preventable cancers by improving access to the HPV vaccine, which could mean a big bump in sales.
What if every drug in a class posed a risk to the heart--all except one? That's the question we could soon be asking about nonsteroidal anti-inflammatories, or NSAIDs, among the most commonly used drugs in the world.
The planned transcontinental marriage between South America's CFR and South Africa's Adcock Ingram had been on shaky grounds for some time. But the engagement has been officially dissolved, thwarted by a jealous shareholder. The question now is whether the drugmaker will be forced back into the arms of a suitor it has arlready spurned.
The highly publicized insider trading case against SAC Capital Advisors trader Mathew Martoma has finally come to a conclusion--at least for now.
New Jersey-based Celgene in 2011 tucked a notice into a financial report that a U.S. Attorney in California was investigating its marketing of its cancer meds Revlimid and Thalomid. Nothing more was said until Thursday when the company divulged that the probe was tied to lawsuits filed against it by whistleblowers.
The risks of women developing a blood clot while using certain contraceptives are well known and have spawned thousands of lawsuits and resulted in billions of dollars in payments. Now it is Merck's turn to pony up, with a $100 million settlement that some say lets it off cheap.
Last year, Roche appeared to throw in the towel on its breast cancer drug Herceptin in India when it said it would not defend the patent there. But it has come back out swinging with a court action that has messed with this week's launch of a biosimilar from Mylan.
Recently unsealed company documents that are part of litigation over the bleeding risks of Boehringer Ingelheim's blockbuster blood thinner Pradaxa show that officials wanted to soften, or even kill, an internal report that suggested a small group of patients would benefit from regular blood monitoring for bleeding risks, The New York Times reports.
Five days after the FDA announced it would investigate the heart and stroke dangers of testosterone-enhancing drugs, 5 lawsuits were filed against Abbott Laboratories and its spinoff AbbVie by men who claimed they suffered heart attacks or strokes after using one of those products, AndroGel.
Humira, the best-selling drug in the world, continues to power the top and bottom lines for the year-old pharma spinoff AbbVie. But the drugmaker has a pipeline of new products it is looking to get approved, and for that it says it needs some more production capacity.